


Pioneering Vision Restoration
Our journey began in 2017 in Istanbul, when ophthalmologist Dr. İskender Alkın Solmaz recognized the potential of telomere biology to combat presbyopia and other vision-threatening conditions. Building on the Nobel Prize-winning discovery of telomeres’ role in cellular aging, Dr. Solmaz and his team developed a novel approach: topical treatments, like eye drops, that could target aging eye tissues directly while minimizing systemic risks.
Since our founding in 2021 in Toronto, TelomEye has advanced a highly differentiated pipeline, leveraging proprietary formulations and rigorous science. Our lead program targets Fuchs’ Endothelial Corneal Dystrophy (FED), a progressive disease affecting 4% of the population, with the potential to slow or halt its progression—offering an alternative to invasive procedures like corneal transplantation.
Our milestones include securing $1 million in funding at a $10 million valuation, joining JLab Toronto’s prestigious biotech hub, and earning the “Most Inspiring Presentation” award at the 2024 Bio NJ conference from J.P. Morgan and Johnson & Johnson. Today, we are preparing for human trials in early 2026, with a goal to bring our groundbreaking treatment to market by 2027-2028.
TelomEye isn’t just developing a therapy—we’re building a future where vision loss is no longer inevitable.
Meet Our Experience Team Members
Assistant Professor of Ophthalmology
Oculoplastic / Reconstructive Surgery
Cataract and Refractive Surgery
Corneal Transplantation
20+ years in pharma industry
10+ years in telomere science
Professor, Ophthalmology, Laval University
World renowned telomere scientist
Professor of Ophthalmology,
Chief, Division of Cornea and Refractive Surgery
Professor of Ophthalmology,
Cornea External Diseases & Refractive Surgery
Professor of Ophthalmology,
Cornea and External Diseases
Professor of Ophthalmology,
Cornea External Disease & Refractive Surgery
Professor of Ophthalmology,
Fuchs’ Dystrophy & Corneal Transplantation
Vice Chair for Collaborative Research
UC Davis Advisor
Foundation Fighting Blindness President
PhamacoLogic Development Regulatory and Clinical Expert
Founder and leader of Turkey's largest chain of private hospitals, Acibadem Healthcare Group
Chairman of the Board of Trustees of Acibadem University
Board member of IHH Healthcare
Americas Sector Leader for Life Sciences at Ernst & Young LLP
SVP Marketing & Sales Eyetech Pharmaceuticals
Re-Pie Asset Management was established in 2015 in Istanbul.
Re-Pie, continues its operations as a fully comprehensive asset
management company with a portfolio size of 1.65 billion USD.